poisar

Stock

Stoke Therapeutics, Inc. STOK

$32.64-1.40%

Overview

STOK market data

Price History

STOK price chart · 1M
O
33.14
H
33.15
L
32.21
C
32.64
Vol
68,471.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$33.14
Previous Close
$33.10
Day High
$33.15
Day Low
$32.21
52 Week High
$34.87
52 Week Low
$27.38
7 Day Return
+3.87%
30 Day Return
+11.15%
90 Day Return
+5.67%
1 Year Return
+0.66%
Daily Notional Volume
$2.2M
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$0.12
Diluted earnings per share over the trailing twelve months.
Beta
1.23
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-753.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$18.00 – $40.22
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $2B · P/B 5.14 · P/S 73.80.

Company News

10 captured
JP Morgan Reinstates Overweight on Stoke Therapeutics, Announces $40 Price TargetBenzinga · Aug 21, 2026, 7:06 PM
Guggenheim Reiterates Buy on Stoke Therapeutics, Maintains $60 Price TargetBenzinga · Aug 4, 2026, 2:07 PM
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 ResultsBenzinga · Aug 4, 2026, 1:28 PM
Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40Benzinga · Aug 4, 2026, 12:48 PM
Canaccord Genuity Maintains Buy on Stoke Therapeutics, Lowers Price Target to $58Benzinga · Aug 4, 2026, 12:18 PM
Stoke Therapeutics Files Prospectus For Up To $200M ATM Stock Offering; Replaces Prior Program After Selling 4.7M Shares For $146.4M In Net ProceedsBenzinga · Aug 3, 2026, 9:07 PM
8-K filing — Stoke Therapeutics, Inc. (STOK)SEC EDGAR · Aug 3, 2026, 9:06 PM
Stoke To Participate In Pre-NDA FDA Meeting During 2H 2026 As It Plans To Initiate Planned Rolling NDA Submission For Zorevunersen In Q1 2027Benzinga · Aug 3, 2026, 8:04 PM
Stoke Therapeutics Q2 EPS $(0.93) Misses $(0.80) Estimate, Sales $9.325M Beat $6.044M EstimateBenzinga · Aug 3, 2026, 8:02 PM
Goldman Sachs Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $44Benzinga · Jul 13, 2026, 9:43 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock